All In Biotech

Drug Trial Radar · NCT03059992

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

233

Actual

Start

Apr 1, 2017

Primary completion

Aug 25, 2023

Study completion Aug 25, 2023

Sponsor

Lead sponsor
Scynexis, Inc.Industry
Sponsor type
Industry
First posted
Feb 23, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.

Conditions

  • Invasive Candidiasis
  • Mucocutaneous Candidiasis
  • Coccidioidomycosis
  • Histoplasmosis
  • Blastomycosis
  • Chronic Pulmonary Aspergillosis
  • Allergic Bronchopulmonary Aspergillosis
  • Invasive Pulmonary Aspergillosis
  • Recurrent Vulvovaginal Candidiasis
  • Other Emerging Fungi

Interventions

  • IbrexafungerpDrug

    Experimental Study Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieve a Global Response as Determined by the Data Review Committee (DRC) by Fungal Disease.Time frame: Vulvovaginal Candidiasis: Day 17. Chronic Mucocutaneous Candidiasis: EOT up to Day 84. Chronic Pulmonary Aspergillus and Allergic Bronchopulmonary Aspergillosis: EOT up to Day 90. All other diseases: EOT up to Day 180. All Days measured from Baseline.

Locations

37 sites in 8 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • UC Davis Medical Center

    Sacramento, California

  • University of California San Francisco

    San Francisco, California

  • Emory University Hospital Midtown

    Atlanta, Georgia

  • Augusta University

    Augusta, Georgia

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Wayne State University

    Detroit, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Weill Cornell Medical College

    New York, New York

  • Stony Brook University Medical Center

    Stony Brook, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Wake Forest Baptist Medical Center

    Winston-Salem, North Carolina

  • University of Pittsburg Medical Center

    Pittsburgh, Pennsylvania

  • University of Texas Southwestern Medical Center Dallas

    Dallas, Texas

  • University of Texas Health Science Center at Houston

    Houston, Texas

  • University of Wisconsin

    Madison, Wisconsin

  • Medical University of Graz Department of Internal Medicine, Department of Pulmology, Section for Infectious Disease and Tropical Medicine

    Graz, Austria

  • Medical University Innsbruck

    Innsbruck, Austria

  • Universitätsklinikum Köln, Klinik I für Innere Medizin

    Cologne, Germany

  • Universitätsklinikum Essen, Klinik für Infektiologie

    Essen, Germany

  • Universitätsklinikum Frankfurt, Department of Internal Medicine II

    Frankfurt, Germany

  • Klinikum St. Georg gGmbH Department for Infectious Disease, Tropical Medicine and Nephrology

    Leipzig, Germany

  • LMU Klinikum der Universität München, Medizinische Klinik und Poliklinik III

    Munich, Germany

  • Radboud University Medical Center, Department of Medicine Geert Grooteplein Zuid 8

    Nijmegen, Gelderland, Netherlands

  • Aga Khan University

    Karachi, Pakistan

  • Emmed Research

    Pretoria, South Africa

  • Johese Clinical Research

    Lyttelton, Centurion, South Africa

  • Into Research

    Groenkloof, Pretoria, South Africa

  • FCRN Clinical Trial Centre

    Three Rivers, Vereeniging, South Africa

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain

  • Hospital Universitari i Politecnic La Fe

    Valencia, Spain

  • St. George's University of London

    London, United Kingdom

  • The University of Manchester

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.